info@sheller.com • PA:215-790-7300 • NJ:609-941-2596
800-883-2299
 

News & Media

NEWS: Stephen Sheller interviewed on WHYY about Whistleblower/False Claims Act cases

WHYY Philadelphia National Public Radio

2010-02-02 -
Why people blow the whistle, and what they get out of it

By: Kerry Grens, senior health and science reporter at Philadelphia National Public Radio WHYY

Last year, several federal juries in Philadelphia returned the largest ever settlements against drug companies. These lawsuits, which resulted in billions in fines, were spurred by a handful of whistleblowers. WHYY's Kerry Grens looks at the growing phenomenon of the whistleblower suit.

Allen Jones comes across as …. intense. He lives in a cabin he built in the woods of Snyder County Pennsylvania. He speaks in a very direct and exacting manner. He smokes, and runs his hand through his hair when he gets lost in his thoughts.

Eight years ago, Jones worked as an investigator in Pennsylvania's Office of the Inspector General.

Jones: An issue landed on my desk involving the state pharmacist Stephen Fiorello.

Jones was asked to look into payments Fiorello had received from pharmaceutical companies. To Jones, it seemed obvious. The payments involved a conflict of interest verging on crime.

Jones: As all of this began to emerge, I began to press my supervisor to broaden the investigation from a personnel issue into a fraud issue and to look more closely at what the drug companies were doing.

Jones detected what he saw as a broader pattern of drug companies improperly influencing formularies, the guidelines that governments set for reimbursing drug prescriptions.

Jones:
Everything I'm uncovering here really causes me to suspect the validity of these guidelines. And also to see, with the massive numbers of dollars involved, the motivation to perpetrate the fraud.

But Jones says higher-ups told him not to pursue the case.

Jones: And I kept pushing and I kept pushing and I kept pushing.

Jones felt isolated and ignored.

Jones: It was one of the darkest times of my life. At that point I'm 50 years old. I knew I was going to lose my job at some point. I hoped that I could hold out. But it was very very frightening and very scary.

Jones' premonition was right. He was fired, after he went to the New York Times with his allegations.

But that was hardly the end of the story. Like most whistleblowers, Jones did not give up easily.

Guyer: A real whistleblower is essentially somebody who has to be tenacious and stick with it over a period of time.

Thad Guyer is a Seattle-based lawyer who represents whistleblowers suing their employers for retaliation. He spoke a few months ago at a conference at Drexel University Law School.

He says that besides being tenacious, whistleblowers tend to show an obsessive tendency to adhere to rules, and a belief that if you point out wrong doing, someone's going to fix it.

Guyer: They're simply put together that way. These whistleblowers are not capable, in my opinion, of not blowing the whistle. They just can't tolerate these kinds of dangers and wrong doing going without some accountability.

But others argue that whistleblowers are mostly in it for the money.

Whistleblowers in two massive lawsuits against drug makers Pfizer and Eli Lilly last year earned themselves millions of dollars for their efforts.

This is the way those lawsuits work. A whistleblower finds something amiss and sues the company. If the government has stake in the case, such as fraud against federal programs like Medicare and Medicaid – the U S attorney joins a lawsuit and together they share the settlement.

Sheller: In the Lilly case there was an $800 million fine.

Stephen Sheller is a Philadelphia-based lawyer who represented whistleblowers in the Pfizer and Lilly lawsuits.

Sheller: The funds that the government recovers from this are immense. Lilly is still the largest single drug recovery in history for the government.

In that case, whistleblowers complained that the company was marketing the anti-psychotic drug Zyprexa for illnesses that it wasn't approved for – an illegal practice called off-label marketing.

 

U.S. Attorney Laurie Magid a year ago:

Magid: Off-label promotion is a serious matter. It can lull physicians into thinking that a drug has been approved by the FDA as safe and effective.

Tom Gallagher represented Eli Lilly during the lawsuit. He says the company has systems to respond more effectively to whistleblower complaints internally. .

Gallagher: Nobody's more committed to doing it the right way. It's just bad business to do it the wrong way. And celebrating whistleblowers as the only remedy to this problem is perhaps the wrong perspective.

But whistleblowers are celebrated – and attorney Stephen Sheller says the record-breaking settlements are drawing more of them out of the woodwork.

Sheller: So you do have this issue of the public knowledge that you can be a whistleblower. Secondly, you have layoffs now occuring in the drug industry.

Sheller says he's received calls from former pharmaceutical employees wanting to expose their practices.

The Department of Justice has about a thousand false claims lawsuits waiting for attention – 20 percent of them concern drug companies. Allen Jones's case is one of them. Even after being fired, Jones doggedly kept up his research on state prescription guidelines. That led him to Texas. Jones says he found evidence that drug maker Janssen improperly marketed the anti-psychotic drug Risperdal through state programs.

In 2006, Jones convinced the attorney general in Texas to sue the company.

Jones: It was tremendously vindicating for me. I had been treated like a crazy person. And yet a very deliberate body and competent investigators and attorney general staff found my allegations to be credible enough to pursue a major lawsuit.

The Texas lawsuit is still pending. A spokesperson for Janssen says the case is without merit, and the company follows FDA's marketing rules.

But more recently, Jones received another vindication. About a year ago in Pennsylvania, the former state pharmacist whom Jones had investigated was convicted of accepting drug company kick backs.

 

 

Link to the story, including audio: http://whyy.org/cms/news/health-science/2010/02/01/why-people-blow-the-whistle-and-what-they-get-out-of-it/29471#comments


Top Stories

Sheller Whistleblower Team: $7.3M Astellas Pharma Off-Label Marketing and FCA Settlement

IN THE NEWS: Stephen Sheller Quoted in "Low T Drug Cases Could Be Next MDL, Mass Tort"

Sheller Whistleblower False Claims Act Settlement: Florida Pain Practice Agrees to Pay Government $750,000 
to Settle Allegations of Unperformed Procedures Billed to Medicare

SHELLER FOUNDATION NEWS: Drexel's 11th Street Health Center to Expand; Sheller Gift Supports Center's Mission

IN THE NEWS: Media coverage and video of Sheller, P.C. Risperdal lawsuit settlements; Sheller represents hundreds of boys in J&J Risperdal breast growth litigation

IN THE NEWS: Stephen Sheller Quoted in Bloomberg Business Week on Whistleblowers and the Firm's Recent J&J $2.2B Settlement

NEWS: J&J to Pay at Least $2.5 Billion to Settle Hip Lawsuits

IN THE NEWS: Researchers Backpedal From Their Own Risperdal Study

IN THE NEWS: Sheller, P.C. in the Chronicle of Higher Education "University Researchers Are Seen as Enablers in Latest Major Drug Fraud"

IN THE NEWS: Sheller, P.C. in Philadelphia Inquirer "J&J to pay $2.2B for Improper Promotion of Risperdal"

NEWS: Whistleblower Law Firm Sheller, P.C. Announces $2+ Billion Johnson & Johnson Risperdal Illegal Marketing Civil and Criminal Settlement, Largest for Single Drug in U.S. History

IN THE NEWS: The Pennsylvania Record reports that Sheller attorneys have filed an additional Risperdal case on behalf of Texas client

IN THE NEWS: Sheller Whistleblower UMass medical billing fraud case settles for 66k

NEWS: OIG Medicare/Medicaid Whistleblower Fraud Alert and WSJ story on Physician-owned distributorships (PODs) of medical devices

IN THE NEWS: Attorney Stephen Sheller "Lawyer Spars With FDA Over J&J Risperdal Court Documents"

IN THE NEWS: Stephen Sheller in Philadelphia Inquirer "FDA Slow to Ask J&J for Drug Data"

IN THE NEWS: Stephen A. Sheller, founding partner of Sheller, P.C., was quoted in the The Philadelphia Inquirer article "High Court Sides with Philadelphia Drug Firm"

NEWS: Lipitor May Increase Diabetes Risk

NEWS: FDA Investigates Two Deaths in Zyprexa Patients

IN THE NEWS: Attorney Stephen Sheller Featured Television Panelist Discussing FDA and Pharma Executives, The American Law Journal

NEWS: Dispute Flares Inside FDA Over Safety of Popular Blood-Pressure Drugs

NEWS: SuperLawyers 2013: Seven Sheller, P.C. Attorneys honored, Stephen Sheller for 10th straight year

NEWS: Study of Babies Did Not Disclose Risks, U.S. Finds; Sheller Attorneys Investigating on Behalf of Families

NEWS: NFL & Players Have Their First Day in Court

IN THE NEWS: Sheller, P.C. Settlement Featured in The Legal Intelligencer "Top 10" since 1994

NEWS: Regulator Issues Fraud Alert on Doctor-Owned Distributors

IN THE NEWS: "Justice for All" in the Temple Times newspaper: Sheller Center for Social Justice

NEWS: Sheller Family Foundation Gift Establishes Social Justice Center at Temple University Beasley School of Law

NEWS: Health Care Fraud Cases Yield $4.2 billion

NEWS: Shire agrees to settle ADHD drug inquiry

NEWS: Court says Pfizer can be sued by man who took generic drug

IN THE NEWS: Stephen Sheller quoted in Forbes.com "Will A Court Ruling Usher In Off-Label Promotions?"

IN THE NEWS: Stephen Sheller quoted in Philadelphia Inquirer article "Court Ruling Could Grant Latitude on Drug Claims"

IN THE NEWS: Stephen Sheller profiled in Philadelphia Life Magazine

IN THE NEWS: Sheller Risperdal settlements front page of The Legal Intelligencer

NEWS: Sheller attorneys investigate reports of Allergan Lap-Band injuries and deaths

NEWS: Sheller Client's Mother Asks Judge in Risperdal Trial to Release J&J Report for Jurors

SPEAKER: Attorney Jamie Sheller to present hip implant litigation strategies

IN THE NEWS: Sheller Products Liability Trial in Risperdal Case Opens in Phila.

NEWS: Sheller, P.C. filing center of Bloomberg article "J&J CEO Should Be Forced to Testify Teens Lawyers Say"

NEWS: J&J Settles with Sheller, P.C. client on first day of Risperdal jury trial

IN THE NEWS: Sheller, P.C. profiled in Suburban Life magazine

NEWS: Stephen Sheller quoted by Pharma Gossip Blog on Off-Label Marketing of Drugs

SPEAKER: Attorney Jamie Sheller Featured Speaker at Annual NetDiligence Cyber Risk and Privacy Liability Forum

SPEAKER: Attorney Jamie Sheller presented at the PBI conference "How to Properly Document Settlement Agreements"

NEWS: Sheller, P.C. Attorneys Honored Again in 2012 as SuperLawyers®

LEGAL PUBLICATIONS NEWS: Sheller, P.C. #1 settlement in Pennsylvania, 2010

IN THE NEWS: Stephen Sheller Quoted on Arkansas Risperdal $1.2B verdict in Gannett and Philadelphia Newspapers

NEWS: J&J's Marketing of Risperdal Violated Law, Arkansas Jury Rules, $1.1B Penalty

NEWS: Generic Drugs Proving Resistant to Damage Suits

NEWS: Philadelphia Trial Lawyers Ask First Judicial District to Rethink Mass Torts Rules

IN THE NEWS: Attorney Jamie Sheller Quoted in Lawyers.com Article on Paula Abdul Slip and Fall Lawsuit

NEWS: J&J to Pay $158M in Risperdal Case; Sheller Quoted on Mass Tort Litigation

NEWS: J&J Pushed Risperdal for Kids Without Approval, Memo Shows

NEWS: J&J Opposes Texas in $1 Billion Risperdal Marketing Trial

NEWS: J&J Said to Agree to $1B in Risperdal Marketing Probe

IN THE NEWS: Attorney Stephen Sheller comments on the potential legal issues in the Penn State sexual abuse allegations

NEWS: Sheller, P.C. releases new video series, "What Is a Whistleblower Claim?"

IN THE NEWS: Sheller 'Live Stop' Class Action, Story of Sheller Client in the Philadelphia Daily News

IN THE NEWS: Attorney Jamie Sheller Quoted by Business Insurance on Data Breach Issues

NEWS: Sheller, P.C. Files Lawsuits Over Police 'Live Stop' Tactics

WHISTLEBLOWER WEBINAR: Attorney Stephen Sheller presented LexisNexis program

NEWS: Sheller, P.C. Attorneys Recognized as 2011 SuperLawyers®

IN THE NEWS: Attorney Stephen Sheller Interviewed by FOX on 'Live Stop' Traffic Enforcement Class Action

NEWS: Attorney Stephen Sheller files suit claiming Philly cops use 'live stop' statute to seize cars illegally

NEWS: Jury Finds Risperdal Manufacturer Violated Consumer Laws; Sheller Attorneys Continue to Pursue Justice for Injured Children

TEMPLE U. LAW SCHOOL ROSS MEMORIAL LECTURE: Stephen Sheller Presents Lecture

NEWS: Attorney Stephen Sheller Honored With First "Pioneer" Award at AAJ Conference

NEWS: Sheller Attorneys Win Class Cert. in 'Light' Tobacco, Potential Actual Damages of Billions for Consumers in Minnesota

NEWS: Jamie Sheller is Featured Presenter at DePuy Hip Implant Recall Litigation Conference, November 3, 2010

NEWS: Stephen Sheller quoted in New York Times article "Side Effects May Include Lawsuits"

IN THE COMMUNITY: Stephen Sheller throws first pitch at Philadelphia Phillies

IN THE COMMUNITY: Stephen Sheller Honored by U.S. Commanding General for Iraq for Dedication to PA National Guard

NEWS: Jamie Sheller in Law.com and Legal Intelligencer on Paxil Birth Defects Cases

NEWS: Pennsylvania Higher Education Foundation Announces Sheller Scholarships

NEWS: Sheller, P.C. attorneys honored once again as SuperLawyers®, 2010

NEWS: Shellers Sponsor Pennsylvania National Guard Exhibit at the National Liberty Museum

NEWS: $520 Million Brings Total Sheller Pharma Whistleblower Settlements to $4.2 Billion

CONSUMER ALERT: Sheller, P.C. Attorneys investigating injuries from recalled Nissan vehicles

CONSUMER ALERT: Sheller, P.C. investigating injuries reported by drivers of Toyotas, concern mounts over accidents in models not listed in recall

NEWS: Stephen Sheller quoted on front page of San Francisco Chronicle

NEWS: Stephen Sheller quoted in Legal Intelligencer story about Toyota litigation

NEWS: Jamie Sheller interviewed in The Philadelphia Inquirer about her client injured by MTD Snowthrower

NEWS UPDATE Toyota Recall: Sheller, P.C. Filing National Class Action Against Toyota

NEWS: Stephen Sheller interviewed on WHYY about Whistleblower/False Claims Act cases

NEWS: New Paxil Birth Defects Cases

NEWS UPDATE: Sheller plans filing twenty to thirty more Risperdal/ Invega cases

NEWS: Sheller, P.C. Files Lawsuits Against Manufacturers of Antipsychotic Drugs Risperdal and Invega

CONSUMER ALERT: Recalled Flu Vaccine Prompts Sheller, P.C. Investigation

NEWS: Sheller, P.C. attorney Jamie Sheller appears on special broadcast of The American Law Journal

IN THE COMMUNITY: Shellers honored at National Philanthropy Day Awards

VERDICT: Jamie Sheller represents client in $2.5 million Paxil birth defects verdict

VERDICT: Sheller, P.C. Whistleblower Case: $2.3 Billion Settlement

VERDICT: Sheller, P.C. Whistleblower Case: $1.4 Billion Settlement

CONSUMER ALERT: Is there a link between antidepressants and Autism?


Links / Associations